Bortezomib

Lenalidomide affect expression level of cereblon protein in multiple myeloma cell line RPMI8226

D. Y. Yang, Ren, J. H., Guo, X. N., Guo, X. L., Cai, X. Y., Guo, X. F., and Zhang, J. N., Lenalidomide affect expression level of cereblon protein in multiple myeloma cell line RPMI8226, vol. 14, pp. 13588-13594, 2015.

We investigated the mechanisms of action of immuno­modulatory drug (lenalidomide) on the protein expression of cereblon (CRBN) and their therapeutic targets in the multiple myeloma cell line RPMI8226. The multiple myeloma cell line RPMI8226 was cultured and treated with different concentrations of lenalidomide and bortezomib to determine the proliferation inhibition rate, apoptosis rate, and protein expression of CRBN. The results revealed that both lenalidomide and bortezomib inhibited the proliferation of RPMI8226 and promoted cell apoptosis.

Bortezomib-based treatment of acute antibody-mediated rejection: a case report

Q. Wang, Li, X. L., Xu, X. G., Shi, B. Y., Zhang, Z. M., Li, Z. L., Han, Y., Zhou, W. Q., Chen, C. Q., Cai, M., and Zhang, X., Bortezomib-based treatment of acute antibody-mediated rejection: a case report, vol. 14, pp. 17951-17958, 2015.

Antibody-mediated rejection (AMR) is an important factor affecting survival after renal transplantation. A highly selective proteasome inhibitor, bortezomib, clears activated plasma cells from the body and has important therapeutic effect on AMR. We investigated the effects of bortezomib on AMR in a patient after a second renal transplant. Biopsy confirmed the diagnosis of mixed cellular rejection and AMR. Bortezomib was administered on day 1 (1.3 mg/m2), day 4 (1.0 mg/m2), and day 8 (1.0 mg/m2).

Subscribe to Bortezomib